Clinical trial · Observational
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
A Real-world Study of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma
NCT06315101CI-TRIAL-00075149completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chinese Herbal Medicine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lenvatinib combined with Chinese Herbal Medicine
- interventionNames
- Drug: Chinese Herbal Medicine
Primary outcomes (3)
- measure
- Efficacy outcomes
- timeFrame
- after 8 weeks of the initiation of Lenvatinib combined with Chinese Herbal Medicine
- description
- Tumor Response after 8 weeks of treatment according to the modified Response Evaluation Criteria in Solid Tumor (mRECIST)
- measure
- Survival analysis
- timeFrame
- 2022/10/01-2023/12/31
- description
- Kaplan-Meier estimates of overall survival (OS)
- measure
- Survival analysis
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * at least 18 years old * histologically confirmed HCC unsuitable for resection * lenvatinib as first- or second-line therapy Exclusion Criteria: * patients with other primary tumors * patients who had only one visit record and were lost to follow-up or refused follow-up * patients with any other factors affecting study data collection
References
Publications (0)
Data not yet available
No reference posted for this study.